This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Comment: Illumina's new PacBio remedies offer suggests it still harbors hope

By Victoria Ibitoye ( November 20, 2019, 16:41 GMT | Comment) -- DNA sequencer Illumina’s revised proposals to resolve UK antitrust concerns over its Pacific Biosciences acquisition suggests its hopes for the deal remain alive. The San Diego-based company has offered to permanently license thousands of its own and PacBio's patents — a significant concession that will require serious consideration by the Competition and Markets Authority.DNA sequencer Illumina’s revised proposals to resolve UK antitrust concerns over its Pacific Biosciences acquisition suggests its hopes for the deal remain alive. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login